Corey Smith

List of Publications by Year
in descending order

83 papers	3,178 citations	172457 29 h-index	175258 52 g-index
90 all docs	90 docs citations	90 times ranked	5106 citing authors

#	Article	IF	Citations
1	A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15440-15445.	7.1	226
2	Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigenâ€“specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood, 2006, 108, 2280-2289.	1.4	215
3	Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. Cancer Discovery, 2019, 9, 1754-1773.	9.4	173
4	Effective Treatment of Metastatic Forms of Epstein-Barr Virusâ€“Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy. Cancer Research, 2012, 72, 1116-1125.	0.9	159
5	Autologous T-cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastoma. Cancer Research, 2014, 74, 3466-3476.	0.9	155
6	BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies. Clinical Microbiology Reviews, 2017, 30, 503-528.	13.6	154
7	Galectin-1 mediated suppression of Epstein-Barr virusâ€“specific T-cell immunity in classic Hodgkin lymphoma. Blood, 2007, 110, 1326-1329.	1.4	145
8	CD8+ TÂcells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. Immunity, 2021, 54, 1055-1065.e5.	14.3	145
9	Epstein-Barr virusâ€“specific T cell therapy for progressive multiple sclerosis. JCI Insight, 2018, 3, .	5.0	105
10	Compartmentalization of Total and Virus-Specific Tissue-Resident Memory CD8+ T Cells in Human Lymphoid Organs. PLoS Pathogens, 2016, 12, e1005799.	4.7	74
11	Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial. Clinical Infectious Diseases, 2019, 68, 632-640.	5.8	72
12	Epsteinâ€“Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1541-1544.	3.0	67
13	Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9319-9324.	7.1	66
14	Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirusâ€specific Tâ€cells in patients with glioblastoma multiforme. Immunology and Cell Biology, 2012, 90, 872-880.	2.3	66
15	Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition. JCI Insight, 2016, 1, e87102.	5.0	66
16	Functional Reversion of Antigen-Specific CD8+ T Cells from Patients with Hodgkin Lymphoma following In Vitro Stimulation with Recombinant Polyepitope. Journal of Immunology, 2006, 177, 4897-4906.	0.8	63
17	Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-/nonself-recognition. Blood, 2009, 114, 2244-2253.	1.4	61
18	Acquisition of Polyfunctionality by Epstein-Barr Virus-Specific CD8 ⁺ T Cells Correlates with Increased Resistance to Galectin-1-Mediated Suppression. Journal of Virology, 2009, 83, 6192-6198.	3.4	51

#	Article	IF	Citations
19	Adoptive Tâ€cell immunotherapy for ganciclovirâ€resistant CMV disease after lung transplantation. Clinical and Translational Immunology, 2015, 4, e35.	3.8	48
20	Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xenoâ€free CTS Immune Cell Serum Replacement. Clinical and Translational Immunology, 2015, 4, e31.	3.8	48
21	Naive CD8⁺ Tâ€cell precursors display structured TCR repertoires and composite antigenâ€driven selection dynamics. Immunology and Cell Biology, 2015, 93, 625-633.	2.3	48
22	Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation. Blood, 2009, 113, 6148-6152.	1.4	47
23	Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response. OncoImmunology, 2017, 6, e1273311.	4.6	41
24	Induction of Pluripotent Protective Immunity Following Immunisation with a Chimeric Vaccine against Human Cytomegalovirus. PLoS ONE, 2008, 3, e3256.	2.5	37
25	Profiling HPV-16â€“specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients. Journal of Experimental Medicine, 2020, 217, .	8.5	37
26	Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme. Journal of Clinical Investigation, 2020, 130, 6041-6053.	8.2	37
27	The Impact of a Large and Frequent Deletion in the Human TCR Î² Locus on Antiviral Immunity. Journal of Immunology, 2012, 188, 2742-2748.	0.8	36
28	Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases. Expert Review of Vaccines, 2013, 12, 661-676.	4.4	33
29	Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. Journal of General Virology, 2011, 92, 1021-1031.	2.9	30
30	Autophagy and proteasome interconnect to coordinate crossâ€presentation through MHC class I pathway in B cells. Immunology and Cell Biology, 2016, 94, 964-974.	2.3	30
31	The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumorâ€infiltrating TÂcells. Immunology and Cell Biology, 2019, 97, 152-164.	2.3	29
32	Essential Developmental, Genomic Stability, and Tumour Suppressor Functions of the Mouse Orthologue of hSSB1/NABP2. PLoS Genetics, 2013, 9, e1003298.	3.5	28
33	Prophylactic and therapeutic strategies for Epsteinâ€“Barr virus-associated diseases: emerging strategies for clinical development. Expert Review of Vaccines, 2019, 18, 457-474.	4.4	26
34	Endogenous antigen presentation impacts on T-box transcription factor expression and functional maturation of CD8+ T cells. Blood, 2012, 120, 3237-3245.	1.4	25
35	The presentation of SARS-CoV-2 peptides by the common HLA-Aâˆ—02:01 molecule. IScience, 2021, 24, 102096.	4.1	23
36	Cytokine-Mediated Loss of Blood Dendritic Cells During Epstein-Barr Virusâ€“Associated Acute Infectious Mononucleosis: Implication for Immune Dysregulation. Journal of Infectious Diseases, 2015, 212, 1957-1961.	4.0	22

#	Article	IF	Citations
37	Impaired Epstein-Barr Virus-Specific Neutralizing Antibody Response during Acute Infectious Mononucleosis Is Coincident with Global B-Cell Dysfunction. Journal of Virology, 2015, 89, 9137-9141.	3.4	21
38	Rapid detection of SARSâ€CoVâ€2â€specific memory Tâ€cell immunity in recovered COVIDâ€19 cases. Clinical and Translational Immunology, 2020, 9, e1219.	3.8	21
39	Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities. Expert Review of Vaccines, 2017, 16, 377-390.	4.4	20
40	Molecular Imprint of Exposure to Naturally Occurring Genetic Variants of Human Cytomegalovirus on the T cell Repertoire. Scientific Reports, 2014, 4, 3993.	3.3	19
41	The Development of Prophylactic and Therapeutic EBV Vaccines. Current Topics in Microbiology and Immunology, 2015, 391, 455-473.	1.1	19
42	Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma. Npj Precision Oncology, 2021, 5, 24.	5.4	19
43	Novel autologous T-cell therapy for drug-resistant cytomegalovirus disease after lung transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 685-687.	0.6	18
44	Adoptive cellular immunotherapy for virusâ€associated cancers: a new paradigm in personalized medicine. Immunology and Cell Biology, 2017, 95, 364-371.	2.3	17
45	Priming of transcriptional memory responses via the chromatin accessibility landscape in T cells. Scientific Reports, 2017, 7, 44825.	3.3	16
46	B cellâ€derived circulating granzyme B is a feature of acute infectious mononucleosis. Clinical and Translational Immunology, 2015, 4, e38.	3.8	15
47	Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16058.	4.1	15
48	Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis. Blood Advances, 2019, 3, 1774-1777.	5.2	15
49	Molecular Basis of a Dominant SARS-CoV-2 Spike-Derived Epitope Presented by HLA-A*02:01 Recognised by a Public TCR. Cells, 2021, 10, 2646.	4.1	15
50	T Cell Cross-Reactivity between a Highly Immunogenic EBV Epitope and a Self-Peptide Naturally Presented by HLA-B*18:01+ Cells. Journal of Immunology, 2015, 194, 4668-4675.	0.8	14
51	T cell repertoire remodeling following post-transplant T cell therapy coincides with clinical response. Journal of Clinical Investigation, 2019, 129, 5020-5032.	8.2	14
52	SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants. PLoS Pathogens, 2022, 18, e1010339.	4.7	13
53	Generating functional CD8⁺ T cell memory response under transient CD4⁺ T cell deficiency: Implications for vaccination of immunocompromised individuals. European Journal of Immunology, 2008, 38, 1857-1866.	2.9	12
54	A new approach for cellular immunotherapy of nasopharyngeal carcinoma. OncoImmunology, 2012, 1, 1440-1442.	4.6	12

#	Article	IF	Citations
55	Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity. Human Vaccines and Immunotherapeutics, 2014, 10, 1064-1077.	3.3	12
56	Tâ€cell adoptive immunotherapy for BK nephropathy in renal transplantation. Transplant Infectious Disease, 2020, 22, e13399.	1.7	11
57	Proteomeâ€wide analysis of Tâ€cell response to BK polyomavirus in healthy virus carriers and kidney transplant recipients reveals aÂunique transcriptional and functional profile. Clinical and Translational Immunology, 2020, 9, e01102.	3.8	11
58	Rapid wholeâ€blood assay to detect SARSâ€CoVâ€2â€specific memory Tâ€cell immunity following a single dose of AstraZeneca ChAdOx1â€S COVIDâ€19 vaccine. Clinical and Translational Immunology, 2021, 10, e1326.	3.8	11
59	Impact of preâ€therapy glioblastoma multiforme microenvironment on clinical response to autologous CMVâ€specific Tâ€cell therapy. Clinical and Translational Immunology, 2019, 8, e01088.	3.8	10
60	Pretransplant Cytomegalovirus-Specific Cellular Immunity and Risk of Viral Reactivation Following Lung Transplantation: A Prospective Cohort Study. Journal of Infectious Diseases, 2021, 224, 312-317.	4.0	10
61	The role of Tâ€cell immunity in COVIDâ€19 severity amongst people living with type II diabetes. FEBS Journal, 2021, 288, 5042-5054.	4.7	9
62	Cellular immune therapy for viral infections in transplant patients. Indian Journal of Medical Research, 2013, 138, 796-807.	1.0	9
63	Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors. Immunotherapy, 2015, 7, 563-572.	2.0	8
64	Epigenetic programming of T cells impacts immune reconstitution in hematopoietic stem cell transplant recipients. Blood Advances, 2018, 2, 656-668.	5.2	8
65	Herpesvirus vaccines: Challenges and future prospects. Hum Vaccin, 2010, 6, 1062-1067.	2.4	7
66	Differential Outcome of IL-2/Antiâ€“IL-2 Complex Therapy on Effector and Memory CD8+ T Cells following Vaccination with an Adenoviral Vector Encoding EBV Epitopes. Journal of Immunology, 2011, 186, 5784-5790.	0.8	7
67	Phenotypic and transcriptional profile correlates with functional plasticity of antigenâ€specific CD4 + T cells. Immunology and Cell Biology, 2014, 92, 181-190.	2.3	7
68	'Off-the-shelfâ€™ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies. , 2021, 9, e001608.		7
69	EBV and nasopharyngeal carcinoma: a target for cellular therapies. Immunotherapy, 2013, 5, 821-824.	2.0	6
70	Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution. Journal of Virology, 2016, 90, 7497-7507.	3.4	6
71	Generation of Cytotoxic T Lymphocytes for Immunotherapy of EBV-Associated Malignancies. Methods in Molecular Biology, 2010, 651, 49-59.	0.9	6
72	Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors. Trends in Molecular Medicine, 2021, 27, 75-90.	6.7	5

#	Article	IF	Citations
73	Expression of CD49f defines subsets of human regulatory TÂcells with divergent transcriptional landscape and function that correlate with ulcerative colitis disease activity. Clinical and Translational Immunology, 2021, 10, e1334.	3.8	5
74	Limited Recognition of Highly Conserved Regions of SARS-CoV-2. Microbiology Spectrum, 2022, 10, e0278021.	3.0	5
75	Immune-based therapeutic approaches to virus-associated cancers. Current Opinion in Virology, 2018, 32, 24-29.	5.4	4
76	Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET). BMC Infectious Diseases, 2022, 22, 70.	2.9	4
77	Synergism between active listeriolysin O and dimethyldioctadecylammonium bromide to activate CD8+ T cells. Vaccine, 2005, 23, 4481-4488.	3.8	3
78	Pre-Existing Cellular Immunity to SARS-CoV-2 Through an Immunodominant Epitope. SSRN Electronic Journal, 0, , .	0.4	2
79	Protocol for purification and identification of MHC class I immunopeptidome from cancer cell lines. STAR Protocols, 2021, 2, 100385.	1.2	1
80	Epstein?Barr virus-associated malignancies: pathobiology and emerging therapeutic options. Microbiology Australia, 2013, 34, 120.	0.4	1
81	Nasopharyngeal Carcinoma Immunotherapy: Current Strategies and Perspectives. Advances in Experimental Medicine and Biology, 2013, , 173-186.	1.6	0
82	Early Cytomegalovirus Reactivation after Allogenic Bone Marrow Transplantation Is Associated with the Loss of Recipient-Derived Humoral Immunity and Is Reduced By IL-6 Inhibition. Blood, 2021, 138, 648-648.	1.4	0
83	Humoral and cellular immune response to Sars-CoV-2 wild-type and variants of concern following 3-dose vaccination in a large cohort of adults with cancer: The SerOzNET study.. Journal of Clinical Oncology, 2022, 40, LBA12065-LBA12065.	1.6	0